GlassScriptPhysician profile
Sina Khasani
NPI 1790704948
$2,091.98
in general payments reported to CMS, 2019-2025
28 companies · $246 in 2025
The $246 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.79 · 2020: $274 · 2021: $773 · 2022: $600 · 2023: $141 · 2024: $32.54 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $579.60 | 2021-2025 | |
| Ucb, INC. | $181.92 | 2020-2022 | |
| Pfizer INC. | $162.80 | 2023-2025 | |
| Adamas Pharmaceuticals, INC. | $159.86 | 2020-2021 | |
| Sk Life Science, INC. | $132.87 | 2020-2022 | |
| Acadia Pharmaceuticals INC | $88.81 | 2021-2023 | Nuplazid |
| Amgen INC. | $80.09 | 2023-2025 | Aimovig, Uplizna |
| Greenwich Biosciences, INC. | $71.95 | 2020-2021 | |
| Lilly USA, LLC | $68.64 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $64.76 | 2021 | |
| Eisai INC. | $52.78 | 2021-2022 | |
| Allergan, INC. | $47.56 | 2020 | |
| Neurocrine Biosciences, INC. | $44.38 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $43.00 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $38.95 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $36.05 | 2020-2021 | |
| Banner Life Sciences, LLC | $30.35 | 2022 | |
| Medtronic USA, INC. | $24.79 | 2019 | |
| Abbott Laboratories | $23.89 | 2025 | Infinity |
| Avanir Pharmaceuticals, INC. | $23.06 | 2022 | |
| Amneal Pharmaceuticals LLC | $19.83 | 2022 | |
| Avion Pharmaceuticals | $18.11 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.99 | 2024 | |
| Jazz Pharmaceuticals INC. | $17.86 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.66 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.56 | 2025 | |
| Genentech USA, INC. | $14.17 | 2023 | Enspryng, Ocrevus |
| Biogen, INC. | $12.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sina Khasani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.